Dementia

Rooted in innovation, BioPharma Diagnostics offers pioneering testing to detect newly discovered biomarkers associated with Alzheimer's disease and other neurodegenerative conditions. Our research-only testing reflects the latest scientific breakthroughs, was thoughtfully developed by neurology experts, and is available exclusively to BioPharma Diagnostics clients to meet clinical trial needs.

Key testing

• Neurology 4-plex (Aβ40, Aβ42, GFAP, Nf-L), Plasma
  • This assay simultaneously measures four biomarkers: Abeta 40 (Aβ40), Abeta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and Nf-L. Each biomarker has been demonstrated to have significance for the investigation of neurodegeneration and brain injury, and to have utility for monitoring effectiveness of drug discovery and development for neurological disease.
  • Blood-based testing for Aβ40, Aβ42, and GFAP is available only for BioPharma Diagnostics clients.
• Phosphorylated Tau₁₈₁, Plasma
  • Phosphorylated tau₁₈₁ (p-tau₁₈₁) in blood is being evaluated as a less invasive biomarker to assess Alzheimer's disease pathology. Phosphorylated tau₁₈₁ concentrations have been shown to be associated with currently approved Alzheimer's disease biomarker measurements, including amyloid-PET and CSF p-tau₁₈₁. In clinical trials, screening individuals with blood biomarkers such as p-tau₁₈₁ represents a less invasive, less costly alternative for enrollment in clinical trials.
  • Blood-based testing for p-tau₁₈₁ is available only for BioPharma Diagnostics clients.